Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annett Keller

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Therapeutic Innovation & Regulatory Science|April 2, 2024
An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) ConsortiumBjörn Koneswarakantha, Ronojit Adyanthaya, Jennifer Emerson, et al.
Therapeutic Innovation & Regulatory Science|July 2, 2026
Understanding the Added Value of Action Limits for QTL MonitoringNathalie van Borrendam, Annett Keller, Leon Els, et al.
Diabetes, Obesity & Metabolism|July 13, 2019
Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trialGilbert Ledesma, Guillermo E Umpierrez, John E Morley, et al.
Therapeutic Innovation & Regulatory Science|February 6, 2024
Quality Tolerance Limits: A General Guidance for Parameter Selection and Threshold SettingAnnett Keller, Nathalie van Borrendam, Patrice Benner, et al.
Diabetology International|January 22, 2021
Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trialTakashi Kadowaki, Guang Wang, Julio Rosenstock, et al.
Diabetes, Obesity & Metabolism|November 13, 2020
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trialMark A Espeland, Richard E Pratley, Julio Rosenstock, et al.
JAMA|September 20, 2019
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical TrialJulio Rosenstock, Steven E Kahn, Odd Erik Johansen, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Therapeutic Innovation & Regulatory Science|April 2, 2024
An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) ConsortiumBjörn Koneswarakantha, Ronojit Adyanthaya, Jennifer Emerson, et al.
Therapeutic Innovation & Regulatory Science|July 2, 2026
Understanding the Added Value of Action Limits for QTL MonitoringNathalie van Borrendam, Annett Keller, Leon Els, et al.
Diabetes, Obesity & Metabolism|July 13, 2019
Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trialGilbert Ledesma, Guillermo E Umpierrez, John E Morley, et al.
Therapeutic Innovation & Regulatory Science|February 6, 2024
Quality Tolerance Limits: A General Guidance for Parameter Selection and Threshold SettingAnnett Keller, Nathalie van Borrendam, Patrice Benner, et al.
Diabetology International|January 22, 2021
Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trialTakashi Kadowaki, Guang Wang, Julio Rosenstock, et al.
Diabetes, Obesity & Metabolism|November 13, 2020
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trialMark A Espeland, Richard E Pratley, Julio Rosenstock, et al.
JAMA|September 20, 2019
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical TrialJulio Rosenstock, Steven E Kahn, Odd Erik Johansen, et al.
Pageof 1